Chemical Structure (Talzenna 01)
Talzenna Capsule, Liquid Filled
Product Images NDC 0069-0655
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Talzenna (NDC 0069-0655). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure 1 (Talzenna 02)
This data presents the Progression-Free Survival for patients treated with Talzenna compared to chemotherapy over a 39-month period, showing the number of patients at risk at different time points. Talzenna treatment appears to sustain a higher number of patients at risk compared to chemotherapy as the months progress.*
Figure 2 (Talzenna 03)
This data shows the overall survival probability of patients using TALZENNA compared to chemotherapy over a period of 60 months. The number of patients at risk at different time intervals is also provided. The graph displays the survival rates of both treatments, indicating the potential benefits of TALZENNA in improving patient outcomes.*
Figure 3 (Talzenna 03a)
This appears to be a comparison between the medication "TALZENNA" plus Enzalutamide versus Placebo plus Enzalutamide. The number of patients in each group is provided as 20 for TALZENNA plus Enzalutamide and 199 for Placebo plus Enzalutamide. Additional information about the impact or results of this comparison is not available in the provided text.*
Logo (Talzenna 04)
This text provides information about the distribution of Pfizer Labs, which is a division of Pfizer Inc. located in New York, NY 10001.*
Logo (Talzenna 04a)
This is a label from Pfizer Labs, a division of Pfizer Inc., based in New York, NY. Pfizer is a well-known pharmaceutical company often associated with the manufacturing and distribution of various medications. The text appears to provide information about distribution contacts.*
Principal Display Panel (0.1 mg Capsule Bottle Label)
The text provides information related to the storage conditions, dosage, and manufacturer details of the medication Talzenna (talazoparib) capsules. It specifies the recommended storage temperature range, precautions, dosage information, as well as the content per capsule. The medication is distributed by Pfizer Labs, a division of Pfizer Inc., and the product is made in Germany. The text also includes the National Drug Code (NDC) for the product.*
Principal Display Panel (0.25 mg Capsule Bottle Label)
This information is the labeling details for Talzenna (talazoparib) capsules. It advises storing the medication at a temperature range of 20°C to 25°C (68°F to 77°F) with excursions between 15°C to 30°C (59°F to 86°F) allowed. The recommended dosage is specified in the Prescribing Information. Each capsule contains 0.25 mg of talazoparib. The product is distributed by Pfizer Labs and is made in Germany. Keep out of reach of children. The National Drug Code (NDC) is 0069-03533.*
Principal Display Panel (0.35 mg Capsule Bottle Label)
This text provides vital information about the storage conditions, dosage recommendation, and contents of Talzenna capsules. The storage temperature range, recommended dosage, and the active ingredient talazoparib's quantity are clearly mentioned. The product is distributed by Pfizer Labs in New York and manufactured in Germany. These capsules are for prescription use only.*
Principal Display Panel (0.5 mg Capsule Bottle Label)
This text provides useful information about storing talazoparib capsules between 20-25°C, with excursions permitted between 15-30°C. It also mentions keeping the medication out of reach of children and provides details about the recommended dosage. The capsules contain 0.5 mg of talazoparib and are distributed by Pfizer Labs. The product is made in Germany and the NDC code is 0069-0546-30. The text also mentions the brand name Talzenna and provides the GTIN as 00300690546308. This information is essential for proper storage and usage of the medication.*
Principal Display Panel (0.75 mg Capsule Bottle Label)
This is a description for Talzenna® capsules distributed by Pfizer Labs. The recommended storage temperature is between 20°C to 25°C (68°F to 77°F), allowing excursions between 15°C to 30°C (59°F to 86°F). Each capsule contains 0.75 mg of talazoparib, which is equivalent to 1.09 mg of talazoparib tosylate. It is essential to keep the product out of reach of children. The medication is prescribed, and the detailed dosage information can be found in the Prescribing Information. The product is made in Germany and has a GTIN of 00300690655307.*
Principal Display Panel (1 mg Capsule Bottle Label)
This is important information regarding the usage and storage of talazoparib capsules. The recommended dosage is noted in the Prescribing Information. Each capsule contains 1 mg of talazoparib. The medication should be kept out of reach of children. It is advised to store the capsules between 15°C to 30°C (59°F to 86°F). The product is distributed by Pfizer Labs in New York, NY and is made in Germany. The package contains 30 capsules and is available by prescription only.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
